GLUE

Monte Rosa Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website monterosatx.com
Employees(FY) 133
ISIN US61225M1027

Performance

-11.04%

-16.61%

+10.88%

+95.76%

+22.65%

YTD

+28.33%

Profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of GLUE 2024-12-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 30 indicating a bearish outlook, while the Oscillators Score of 53 suggests a neutral stance, and the Technical Score at 41 also leans towards bearish. Overall, the combined scores imply a cautious market sentiment, with potential for volatility as the indicators do...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GLUE

Stock Rank

Recent News & Updates

2024-12-12 18:00
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors(Globenewswire)
2024-12-11 07:48
Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression(MT Newswires)
2024-12-11 07:45
Monte Rosa Closes Global License Agreement With Novartis(MT Newswires)
2024-12-11 07:00
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer(GlobeNewswire)
2024-12-11 07:00
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders(GlobeNewswire)
2024-12-10 18:00
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer(Globenewswire)
2024-12-10 18:00
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders(Globenewswire)
2024-12-06 07:11
Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study(TipRanks)
2024-12-05 07:00
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors(GlobeNewswire)
2024-12-04 18:00
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors(Globenewswire)
2024-12-02 17:44
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?(Zacks)
2024-11-26 07:00
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference(GlobeNewswire)
2024-11-25 18:00
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference(Globenewswire)
2024-11-14 20:55
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet(Yahoo Finance)
2024-11-13 07:00
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference(GlobeNewswire)
2024-11-12 18:00
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference(Globenewswire)
2024-11-11 07:45
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),(Simply Wall St.)
2024-11-07 08:35
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates(Zacks)
2024-11-07 07:30
Monte Rosa Therapeutics: Q3 Earnings Snapshot(Associated Press Finance)
2024-11-07 07:00
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update(GlobeNewswire)
2024-11-06 18:00
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-11-06 12:00
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice(Zacks)
2024-10-30 09:55
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade(Zacks)
2024-10-29 11:50
Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler(TipRanks)
2024-10-29 10:57
Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis(GuruFocus.com)
2024-10-28 17:40
Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis(Investor's Business Daily)
2024-10-28 14:37
Top Midday Gainers(MT Newswires)
2024-10-28 14:26
This Biotech Stock Has Doubled Its Value Today—Here's Why(Investopedia)
2024-10-28 10:38
Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $15 From $11, Maintains Outperform Rating(MT Newswires)
2024-10-28 07:47
Monte Rosa Therapeutics Enters Global License Deal With Novartis; Shares Jump Pre-Bell(MT Newswires)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.